Bristol-Myers Squibb (NYSE: BMY) acquired its peer Celgene (NASDAQ: CELG) in a $74-billion cash-and-stock deal. Under the agreement terms, Celgene shareholders will receive 1 BMY share and $50 in cash … Continue reading Bristol-Myers Squibb swallows Celgene for $74-bln; Celgene stock surges